4D Molecular Therapeutics announces first patient dosed in Phase 1/2 Clinical Trial of 4D-150

According to the company, 4D-150 is a dual-transgene, intravitreal gene therapy designed to inhibit four distinct angiogenic factors to prevent angiogenesis and reduce vascular permeability for the treatment of wet AMD.